全文获取类型
收费全文 | 1988篇 |
免费 | 102篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 94篇 |
妇产科学 | 129篇 |
基础医学 | 287篇 |
口腔科学 | 111篇 |
临床医学 | 158篇 |
内科学 | 279篇 |
皮肤病学 | 40篇 |
神经病学 | 206篇 |
特种医学 | 118篇 |
外科学 | 194篇 |
综合类 | 41篇 |
预防医学 | 106篇 |
眼科学 | 2篇 |
药学 | 178篇 |
中国医学 | 1篇 |
肿瘤学 | 140篇 |
出版年
2023年 | 15篇 |
2022年 | 21篇 |
2021年 | 45篇 |
2020年 | 24篇 |
2019年 | 42篇 |
2018年 | 36篇 |
2017年 | 46篇 |
2016年 | 37篇 |
2015年 | 45篇 |
2014年 | 53篇 |
2013年 | 70篇 |
2012年 | 115篇 |
2011年 | 127篇 |
2010年 | 69篇 |
2009年 | 71篇 |
2008年 | 96篇 |
2007年 | 92篇 |
2006年 | 93篇 |
2005年 | 100篇 |
2004年 | 84篇 |
2003年 | 61篇 |
2002年 | 73篇 |
2001年 | 63篇 |
2000年 | 62篇 |
1999年 | 77篇 |
1998年 | 54篇 |
1997年 | 41篇 |
1996年 | 19篇 |
1995年 | 22篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 24篇 |
1991年 | 26篇 |
1990年 | 21篇 |
1989年 | 27篇 |
1988年 | 17篇 |
1987年 | 20篇 |
1986年 | 21篇 |
1985年 | 18篇 |
1984年 | 9篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1978年 | 8篇 |
1976年 | 8篇 |
1972年 | 11篇 |
1970年 | 8篇 |
1969年 | 10篇 |
1968年 | 9篇 |
排序方式: 共有2109条查询结果,搜索用时 15 毫秒
1.
A. Farina 《Journal of pharmaceutical and biomedical analysis》1989,7(12):1579-1583
A simple and rapid fluorimetric method for the determination of 9-fluoro-10-[N-(4′-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-d,e][1–4]benzothyazin-6-carboxylic acid hydrochloride (MF 934), in serum and in pharmaceutical formulations, has been developed based on its strong fluorescence, in 0.1 N H2SO4, at 526 nm (excitation wavelength at 340 nm). The procedure which involves the direct dilution of the sample requires only a few minutes and the sample volume is only 20–100 μl of serum, depending on the drug concentration. Tedious sample preparation procedures such as extraction, deproteinization, or centrifugation are not necessary. The minimum concentration that can be detected is 0.3 ng ml−1, the standard curve in 0.1 N H2SO4 was found to be linear from 0.005 to 1.5 μg ml−1 and from 0.01 to 0.07 g in plasma after dilution with 0.1 N H2SO4. 相似文献
2.
3.
4.
Roberto Farina M.D. 《Aesthetic plastic surgery》1987,11(1):249-253
Keratodermia is an incurable genetic and regional disease located in the palmar and plantar regions. The author reports his experience with five cases of palmoplantar keratodermia that were treated by grafting onto the soles and the palms skin taken from the calves and the thighs. 相似文献
5.
E Benfenati R Fanelli E Bosone R Caponi P Farina 《European journal of drug metabolism and pharmacokinetics》1992,17(2):93-101
The compound IBI-P-05006, 2-(6'-carboxyhexyl)-3-n-hexylcyclohexylamine, is an antiaggregating agent under development. IBI-P-05006 is an in vitro inhibitor of platelet aggregation. The biotransformation of this compound has been studied in the dog and rat. We present here a study on the metabolites of IBI-P-05006 found in dog and rat urine, and in dog plasma. Analyses were done by gas chromatography-mass spectrometry. In dog urine 15 metabolites were identified. Some of them were also found in dog plasma and in rat urine. The unmetabolized drug was found only in plasma. 10 different hydroxylated metabolites were characterized. The hydroxyl groups were introduced in the hexyl chain in positions omega-4, omega-3, omega-2, omega-1 and omega. 相似文献
6.
J Hasegawa R Matsuoka K Ichizuka A Sekizawa A Farina T Okai 《Ultrasound in obstetrics & gynecology》2006,27(4):425-429
OBJECTIVES: To evaluate the accuracy of sonographic identification of the site of umbilical cord insertion (CI) at 18-20 weeks of gestation, to compare the sensitivities for detection of a velamentous cord insertion (VCI) secondary to a CI into the anterior, posterior or fundal wall, and to compare the intrapartum complications secondary to VCI into the upper, middle or lower third of the uterus. METHODS: As part of the routine ultrasound scan at 18-20 weeks' gestation we evaluated abnormal CI (VCI and marginal CI) and the location of the CI in the uterus in 3446 pregnancies. In cases of abnormal CI, the location of the CI was further classified as being in the upper, middle or lower third of the uterus. After delivery, the placenta and the umbilical cord were examined and intrapartum complications were compared with the location of the CI. RESULTS: The values for antenatal detection of VCI were: sensitivity, 25 of 40 (62.5%); positive predictive value, 25 of 25 (100%); and negative predictive value, 3406 of 3421 (99.6%). The sensitivity for cases in which the CI was located on the anterior wall was 12 of 13 (92.3%); when it was located on the posterior wall, the sensitivity was 11 of 22 (50.0%); and when it was fundal the sensitivity was 2 of 5 (40.0%). Variable decelerations were frequently observed with a VCI. In lower VCI cases, non-reassuring fetal heart rate patterns and emergency Cesarean sections occurred with a higher frequency than in cases with upper or middle VCI (P < 0.01). After delivery, the length of the aberrant vessels in cases of VCI by pathologic examination was 3.9 +/- 3.3 cm in the upper third, 4.7 +/- 4.6 cm in the middle third, and 10.6 +/- 6.8 cm in the lower third; thus, the aberrant vessel length was significantly greater when the CI was in the lower third of the uterus (P = 0.024). CONCLUSION: We have demonstrated that VCI with a lower CI site and with longer aberrant vessels is associated with various intrapartum complications. This finding has the potential for improving perinatal outcome. 相似文献
7.
Toxic pustuloderma associated with azithromycin 总被引:1,自引:0,他引:1
8.
AP de Moraes† ÉÂG de Arruda† MAV Vitoriano† MO de Moraes Filho‡ FÂF Bezerra‡ E de Magalhães Holanda§ MEA de Moraes‡ 《Journal of the European Academy of Dermatology and Venereology》2007,21(5):596-601
BACKGROUND: Seborrhoeic dermatitis (SD) is a common dermatosis in human immunodeficiency virus (HIV)-positive patients, many of whom do not respond satisfactorily to conventional topical treatments such as corticosteroids and antifungals. OBJECTIVE: A pilot study to investigate the efficacy and tolerability of pimecrolimus cream 1% in HIV-positive patients with facial SD. METHODS: In a single-centre study, 21 HIV-infected patients with mild to severe SD were treated twice daily with pimecrolimus cream 1% for 14 days. Thereafter, treatment was discontinued and patients followed up for 5 weeks. Skin involvement at baseline and on days 7, 14, 21, 35 and 49 was assessed using a four-point clinical score and digital photography. MAIN OUTCOME MEASURES: Efficacy and safety of pimecrolimus cream 1% treatment and incidence of relapse in the follow-up phase. Results Marked improvement was seen in clinical parameters at day 7, with >or= 90% patients clear of symptoms at day 14. Relapse was observed at day 35 but signs were milder than at baseline. All patients responded to therapy, despite their immunological status. Pimecrolimus did not alter CD4(+) and CD8(+) T-cell counts or viral load during the treatment period. CONCLUSION: Pimecrolimus cream represents a new, effective therapeutic option for facial SD in HIV patients. 相似文献
9.
10.
Emilio Benfenati Pierluigi Farina Tina Colombo Gianluca De Bellis Mauro Valerio Capodiferro Maurizio D'Incalci 《Cancer chemotherapy and pharmacology》1989,24(6):354-358
Summary The pharmacokinetics of the anticancer agent p-(3,3-dimethyl-1-triazeno) benzoic acid (pCOOH-DMT), a drug now in phase I clinical trial in Europe, was investigated in C57 Bl female mice with M5076 reticulum-cell sarcoma that were treated i.v. with 200 mg/kg pCOOH-DMT. The drug disappeared from plasma with a terminal half-life of about 2.5 h. Plasma clearance was approximately 6 ml/min per kg. Distribution studies showed some differences in drug levels in different tissues. The highest levels were found in the tumor, liver, kidney and lung; lower levels were found in the spleen and gut, and the lowest, in the brain. The N-desmethyl derivative of pCOOH-DMT was not detectable in plasma or tissues of mice treated with the drug. Therefore, the previous evidence of low N-demethylation of pCOOH-DMT was confirmed. pCOOH-DMT glucuronide was identified by mass spectrometry and quantified by high-performance liquid chromatography (HPLC) in plasma, tissues and urine samples. pCOOH-DMT glucuronide appears to be the major urinary metabolite of pCOOH-DMT in mice. Another metabolite identified by mass spectrometry and quantified by HPLC in some tissues and urine was pCOOH-DMT glycinate.Abbreviations DTIlC
5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide
- pCOOH-DMT
p-(3,3-dimethyl-l-triazeno)benzoic acid
- pCOOH-MMT
p-(3-methyl-l-triazeno)benzoic acid
- pCONH2-DMT
p-(3,3-dimethyl-l-triazeno)carboxamide
- BSTFA
N,O-bis(trimethylsilyl)trifluoroacetamide
- TMCS
trimethylchlorosilane
- TLC
thin-layer chromatography
- FAB
fast atom bombardment
- EI
electron impact
- M5
M5076 reticulum-cell sarcoma
- t1/2
beta-half-life
- C0
concentration time 0
- AUC
area under the concentration vs time curve
- Cl
total clearance
- V
volume of distribution 相似文献